Ma Zhiqiang, Wang Yanlong, Piao Taikui, Li Zhaopeng, Zhang Hongyu, Liu Zhixin, Liu Jianyu
Department of Orthopedic Surgery, The Second Hospital of Harbin Medical University, Harbin, Heilongjiang Province, 150086, People's Republic of China.
Tumour Biol. 2015 May;36(5):3319-24. doi: 10.1007/s13277-014-2964-z. Epub 2014 Dec 17.
Osteosarcoma is the most common primary bone malignancy; however, the molecular mechanisms of development are not well understood. Progestin and AdipoQ receptors (PAQR3), a protein specifically localized in the Golgi apparatus, was recently characterized as a new tumor suppressor. Little is known about the expression and function of PAQR3 in osteosarcoma. Here, we showed that PAQR3 was downregulated in osteosarcoma tissues compared with the adjacent normal regions in 80 paired samples. Moreover, lower levels of PAQR3 were associated with metastasis in clinical osteosarcoma patients. In addition, overexpression of PAQR3 in the osteosarcoma cell line MG-63 inhibited cell proliferation, migration, and invasion by promoting ERK phosphorylation. Taken together, our results indicated that PAQR3 might act as a tumor suppressor in osteosarcoma, providing a novel diagnostic and therapeutic option for human osteosarcoma in the future.
骨肉瘤是最常见的原发性骨恶性肿瘤；然而，其发展的分子机制尚未完全清楚。孕激素和脂联素受体（PAQR3）是一种特异性定位于高尔基体的蛋白质，最近被鉴定为一种新的肿瘤抑制因子。关于PAQR3在骨肉瘤中的表达和功能知之甚少。在此，我们发现，在80对配对样本中，与相邻正常组织相比，骨肉瘤组织中PAQR3表达下调。此外，临床骨肉瘤患者中PAQR3水平较低与转移相关。另外，在骨肉瘤细胞系MG-63中过表达PAQR3可通过促进ERK磷酸化来抑制细胞增殖、迁移和侵袭。综上所述，我们的结果表明PAQR3可能在骨肉瘤中发挥肿瘤抑制作用，为未来人类骨肉瘤提供了一种新的诊断和治疗选择。
